Related Experiment Video
Updated: Jul 20, 2026

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production
Published on: March 2, 2014
Suppressive effect of simvastatin on interferon-beta-induced expression of CC chemokine ligand 5 in microglia
Kazuo Nakamichi1, Megumi Saiki, Hiroshi Kitani
1Laboratory of Neurovirology, Department of Virology 1, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku, Tokyo, Japan. nakamich@nih.go.jp
Abstract:
Despite the pivotal role of microglia in immune system of the brain, a growing body of evidence suggests that the excessive microglial activation provokes neuronal and glial damages, leading to neurodegenerative and neuroinflammatory disorders. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, have recently received much attention for their suppressive effects on inflammation in the central nervous system. In the current study, we have examined the statin-mediated inhibition of microglial function, especially that of chemokine production. Stimulation of microglial cells with interferon-beta (IFN-beta) resulted in the expression of CC chemokine ligand 5 (CCL5), a major chemoattractant of inflammatory cells. Microglial CCL5 response was synergistically potentiated by costimulation with IFN-beta and tumor necrosis factor-alpha (TNF-alpha). The simvastatin treatment significantly diminished the microglial CCL5 expression induced by IFN-beta alone or by IFN-beta/TNF-alpha combination. In the presence of simvastatin, the IFN-beta-induced activation of Janus kinase (Jak)-signal transducer and activator of transcription (STAT) pathway was attenuated, although this compound had little or no effect on the TNF-alpha-evoked activation of nuclear factor kappaB and c-Jun N-terminal kinase pathways. In addition, chemical inhibitor of Jak-STAT signaling significantly diminished the IFN-beta-induced expression of CCL5 in microglia. Taken together, these results suggest that simvastatin suppresses the IFN-beta-induced expression of CCL5 via down-regulation of Jak-STAT signaling pathway.
Insights
Simvastatin, a type of statin, reduces brain inflammation by inhibiting microglial cells. It suppresses the expression of CC chemokine ligand 5 (CCL5) by down-regulating the Janus kinase-signal transducer and activator of transcription pathway.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Microglia are key brain immune cells, but their overactivation causes neuroinflammation and neurodegeneration.
- Statins show potential in reducing central nervous system inflammation.
Purpose of the Study:
- To investigate how simvastatin inhibits microglial function, focusing on chemokine production.
- To elucidate the molecular mechanisms behind simvastatin's anti-inflammatory effects in microglia.
Main Methods:
- Microglial cells were stimulated with interferon-beta (IFN-beta) and tumor necrosis factor-alpha (TNF-alpha).
- Simvastatin's effect on CC chemokine ligand 5 (CCL5) expression was measured.
- The involvement of Janus kinase (Jak)-signal transducer and activator of transcription (STAT) and nuclear factor kappaB (NF-kB) pathways was analyzed.
Main Results:
- IFN-beta induced CCL5 expression in microglia, potentiated by TNF-alpha.
- Simvastatin significantly reduced IFN-beta-induced CCL5 expression.
- Simvastatin attenuated the IFN-beta-induced Jak-STAT pathway activation but not TNF-alpha-evoked NF-kB and c-Jun N-terminal kinase pathways.
- Jak-STAT pathway inhibition mimicked simvastatin's effect on CCL5 expression.
Conclusions:
- Simvastatin suppresses IFN-beta-induced CCL5 expression in microglia.
- This suppression is mediated through the down-regulation of the Jak-STAT signaling pathway.
- Statins represent a potential therapeutic strategy for neuroinflammatory conditions.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly

